US STOCKS · SEC COMPANY PROFILE
Thermo Fisher Scientific
THERMO FISHER SCIENTIFIC INC. · NYSE
Thermo Fisher Scientific supplies laboratory instruments, consumables, diagnostics and biopharmaceutical services.
Visit Thermo Fisher Scientific’s official websiteReported revenue spread evenly through elapsed UTC time. Refresh does not restart it; it resets at midnight UTC.
For every $100 of reported revenue
2026-01-01–2026-06-27 · ratios from the same reported period
Profit includes accounting items that may not involve cash today. Operating cash flow measures cash from operations; capital spending covers the reported investment measure. These ratios help compare scale, but industry, seasonality and one-time items still matter. They are not a breakdown that adds to $100.
Segments & intercompany deduction
Reported accounting profit can include one-time items; revenue is not cash collected. Segment shares are calculated from consolidated revenue for the same period.
TMO stock price
TradingView supplies updated market data automatically. The chart starts with one-hour intervals; the current interval can change as trades arrive. Exchange delays and availability are shown by the provider.
WORLD NUMBERS ASSESSMENTCompany Health Score
Expand for the score breakdown and outlookSolid overall healthCash, growth, profits and investment · review the assumptions below7/10View details
Company Health Score
Expand for the score breakdown and outlookSolid overall health
Our assessment of the reported financial position and the company-specific outlook.
Higher means stronger overall financial health under this model. This is World Numbers’ subjective assessment, not an official rating or a prediction of the stock price. It does not establish that shares are good value.
$4.06B cash and equivalents against $60.5B total liabilities. This excludes marketable investments.
10.5% change in latest-quarter revenue from the comparable year-earlier quarter.
14.7% net margin for the reported 178-day period. One-time gains or charges can affect this measure.
$2.49B operating cash flow after cash capital spending for the same reported period. This is a calculation, not all investing or financing activity.
Research and biopharma demand can support revenue; customer budgets, acquisitions and clinical project activity affect growth and cash generation.
Looking ahead
Research and biopharma demand can support revenue; customer budgets, acquisitions and clinical project activity affect growth and cash generation. This is a speculative editorial interpretation of the filing’s business and risk discussion, not quantified issuer guidance.
How we arrived at the score
Cash scores use cash ÷ liabilities: at least 0.5 scores 9, 0.25 scores 8, 0.1 scores 6; otherwise 4. Revenue growth scores: at least 30% scores 9, 10% scores 8, non-negative scores 6; otherwise 3. Net margin scores: at least 20% scores 9, 10% scores 8, non-negative scores 6; otherwise 3. Cash after investment ÷ revenue scores: at least 15% scores 9, 5% scores 8, non-negative scores 6; otherwise 3. Future outlook is an editorial score. The weighted result is 6.85, rounded to 7. These thresholds and weights are judgment choices, not statistically validated probabilities. The assessment uses data through 2026-06-27; it does not update each second.
Net income
Latest quarter: $1.74B net income · 14.5% net margin
Q1 2027 at this pace: $1,712,528,090Reported total ÷ 178 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Operating cash flow
Reported cash flow from operations
Q1 2027 at this pace: $1,677,134,831Reported total ÷ 178 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Capital spending
Cash property, plant and equipment purchases; acquisitions and financing are separate.
Q1 2027 at this pace: $417,640,449Reported total ÷ 178 days × elapsed UTC time. Refresh does not restart this estimate; it resets at midnight UTC.Current leadership
Marc N. Casper
Chief executive officer
Leadership is checked separately from annual compensation. The historical pay table below may cover different roles or former executives.
Leadership check and financial reporting dates are separate. Annual total compensation is updated when a new compensation disclosure is published; quarterly earnings do not necessarily include it.
Reported executive pay
Three executives from the dated compensation disclosure. Names, roles and pay below describe that disclosure and do not establish who leads the company today.
Why use this pay period? The latest reviewed proxy reports fiscal 2025 compensation. Its publication date is different from the period being paid. The annual counters illustrate that historical pay across the current calendar year; they are not current payroll.
Marc N. Casper
Historical disclosure: CEO
- Salary reported · 2025
- $1,785,534
- Total pay reported · 2025
- $79,923,350
- Shares held or eligible to buy
- 449,661
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total includes grant-date stock or option accounting values, incentives, benefits and pension adjustments where reported; it is not all cash received. Large equity grants or retention awards can make this annual accounting total unusually high; vesting and performance conditions still apply.
Stephen Williamson
Historical disclosure: CFO
- Salary reported · 2025
- $1,095,170
- Total pay reported · 2025
- $6,781,012
- Shares held or eligible to buy
- 145,024
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total includes grant-date stock or option accounting values, incentives, benefits and pension adjustments where reported; it is not all cash received. Large equity grants or retention awards can make this annual accounting total unusually high; vesting and performance conditions still apply.
Michel Lagarde
Historical disclosure: COO
- Salary reported · 2025
- $1,166,433
- Total pay reported · 2025
- $8,907,174
- Shares held or eligible to buy
- 170,132
- Current value of reported shares
- Not calculated The chart’s quote is provided separately. We do not multiply historical ownership by an unverified price or treat conditional awards as cash.
Total includes grant-date stock or option accounting values, incentives, benefits and pension adjustments where reported; it is not all cash received. Large equity grants or retention awards can make this annual accounting total unusually high; vesting and performance conditions still apply.
Total compensation can include grant-date accounting values of stock or options and benefits. It is not necessarily cash received. Ownership date: 2026-02-28. Beneficial ownership is a dated proxy snapshot and can include options or awards eligible within the disclosed window; it is not a live count or all currently tradable stock. Totals include options and units eligible by April 28, 2026.
Employees
Annual workforce and proxy pay populations can differ. Median compensation is the middle disclosed employee, not average salary. The ratio here uses the first displayed executive’s compensation table total, which can differ from the issuer’s official ratio. Employee counts are reported snapshots and do not tick. Companies use different employee populations and pay-ratio methods, so comparisons need care.
Revenue & net income
Revenue appears in blue above net income in pink. Net margin is net income divided by revenue. These are reported results, not estimates.
2025-06-28
2026-06-27
What changed?
$11.99B versus $10.86B in the comparable quarter a year earlier. The dollar change was $1.14B.
$1.74B net income versus $1.62B a year earlier. Net income includes expenses and other gains or charges; it is not a measure of cash in the bank.
Reported accounting profit can include one-time items; revenue is not cash collected. For the 178-day cash-flow period, operating cash flow less cash capital spending was $2.49B.
Watch next quarter
Research and biopharma demand can support revenue; customer budgets, acquisitions and clinical project activity affect growth and cash generation. Next earnings date: consult the company’s confirmed announcements; no unverified calendar date is displayed.
What was reported at 2026-06-27
Balances update when a new filing is verified. Investment categories differ; only the labeled short-term category is displayed.
Valuation, returns & earnings
Capital returns & voting rights
Dividend and repurchase payments are historical cash flows, not future commitments or dividend yield.
Beneficial ownership is a dated proxy snapshot and can include options or awards eligible within the disclosed window; it is not a live count or all currently tradable stock. Totals include options and units eligible by April 28, 2026. Reported executive ownership is dated 2026-02-28; balances and market values are different measures.
Thermo Fisher Scientific financial questions, explained
How much revenue does Thermo Fisher Scientific generate per day and per second?
The reviewed SEC 10-Q reports $22,999,000,000 from 2026-01-01 through 2026-06-27, covering 178 days. Dividing by those actual days gives $129,207,865 per day and $1,495 per second. The counter illustrates that historical rate across each UTC day; it is not live sales or management guidance. Reported accounting profit can include one-time items; revenue is not cash collected.
Read the SEC sourceWhat were Thermo Fisher Scientific’s latest quarterly revenue and earnings?
For the quarter ended 2026-06-27, revenue was $11,994,000,000 and net income was $1,736,000,000, a 14.5% net margin. Revenue in the comparable year-earlier quarter was $10,855,000,000. Reported net income includes accounting gains, expenses and charges; it is not cash collected.
Read the SEC sourceWhere does Thermo Fisher Scientific’s reported revenue come from?
Segments & intercompany deduction: Life Sciences Solutions: $5,450,000,000 (23.7%); Analytical Instruments: $3,563,000,000 (15.5%); Specialty Diagnostics: $2,346,000,000 (10.2%); Laboratory Products & Biopharma Services: $12,729,000,000 (55.3%); Intersegment deduction: $-1,089,000,000 (-4.7%). These amounts cover 2026-01-01 through 2026-06-27. The negative component is a deduction used to reconcile business amounts to net consolidated revenue; it does not represent negative customer sales. Product and geographic breakdowns are labeled as such and should not be mistaken for separate operating segments.
Read the SEC sourceHow much compensation did Marc N. Casper report at Thermo Fisher Scientific?
The latest reviewed proxy reports $1,785,534 salary and $79,923,350 total compensation for fiscal 2025. CEO. Total includes grant-date stock or option accounting values, incentives, benefits and pension adjustments where reported; it is not all cash received. Large equity grants or retention awards can make this annual accounting total unusually high; vesting and performance conditions still apply. The annual-pay counter is an illustration spread through the current calendar year, not evidence of cash being paid every second.
Read the SEC sourceHow many employees does Thermo Fisher Scientific report, and what is median pay?
The annual filing reports 125,000 employees as of 2025-12-31. The proxy reports median total employee compensation of $71,333 for Fiscal 2025. Median means the middle employee in the disclosed population, not an average base salary. Annual workforce and proxy pay populations can differ. Median compensation is the middle disclosed employee, not average salary. The ratio here uses the first displayed executive’s compensation table total, which can differ from the issuer’s official ratio.
Read the SEC sourceDoes Thermo Fisher Scientific’s operating cash flow cover reported capital spending?
Reported operating cash flow was $3,317,000,000 and cash capital spending was $826,000,000 for the 178-day period. Subtracting spending gives $2,491,000,000. Cash property, plant and equipment purchases; acquisitions and financing are separate. This calculation does not include all investing or financing activity.
Read the SEC sourceDoes Thermo Fisher Scientific pay a cash dividend?
The reviewed period shows $337,000,000 of cash dividend payments. That is a historical total, not dividend yield or a promise about future payments. Dividend and repurchase payments are historical cash flows, not future commitments or dividend yield.
Read the SEC sourceWhat should investors watch in Thermo Fisher Scientific’s next report?
Watch Laboratory and biopharma services, Research budgets and geographic demand, Acquisition integration and debt. Research and biopharma demand can support revenue; customer budgets, acquisitions and clinical project activity affect growth and cash generation. The next-quarter counters hold the reported daily rate unchanged. They are World Numbers scenarios, not issuer guidance or stock-price predictions.
Read the SEC sourceReporting period: 2026-01-01–2026-06-27 · filed 2026-07-31 · last completed verification 2026-10-08 · page updated 2026-10-26
How World Numbers calculates estimatesHow the estimates work
We divide each reported flow by its actual 178-day reporting period. The daily rate is spread evenly over elapsed UTC time and resets at midnight. Refreshing the page does not restart the counter. The next-calendar-quarter illustration holds that pace unchanged; it is not live sales or a company forecast. Annual executive pay is spread across the current calendar year, including leap-year day counts. Stock awards, balances, employees and shares are not current payroll or live counts. Company-specific limitations: Reported accounting profit can include one-time items; revenue is not cash collected.